Darmiyan
Darmiyan is a neuroscience-AI company whose FDA De Novo-approved BrainSee software (January 2024) provides the first AI-powered prognosis of Alzheimer's disease in patients with amnestic mild cognitive impairment, using its proprietary DarmiScope MRI analysis platform to serve healthcare providers, pharmaceutical companies, and senior-care networks.
- Company typePrivate
- Founded2016
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Darmiyan does
Darmiyan is a neuroscience-AI company founded in 2016 that develops software for early detection, monitoring, and prognosis of Alzheimer's disease. Its core technology, the DarmiScope Virtual Microscope, performs cellular-level analysis of every voxel (3D pixel) of a standard clinical brain MRI scan to extract novel biomarkers of neurodegeneration, built on four decades of pioneering brain research and protected by patents granted in the US and Japan with filings in Europe and Asia. The flagship commercial product, BrainSee, combines a patient's brain MRI with cognitive test scores to produce a 0–100 score indicating the likelihood of progression from amnestic mild cognitive impairment (aMCI) to Alzheimer's dementia; BrainSee received FDA Breakthrough Device Designation in May 2021 and FDA De Novo approval in January 2024, making it the first FDA-approved medical software in this prognostic indication.
The company serves three primary customer segments: healthcare providers (neurologists, radiologists, neuroradiologists, and primary care physicians evaluating patients with memory complaints); pharmaceutical companies seeking objective measures to identify prodromal biomarkers and support Alzheimer's drug development (anchored by Eisai, which led the 2020 Series Seed); and health facilities and senior-care networks, most notably the California Association of Health Facilities (CAHF), which in November 2025 designated Darmiyan as its preferred provider for cognitive health solutions across member facilities serving 350,000+ California residents. Distribution is enterprise field sales with direct engagement of hospitals, clinics, and MR imaging centers, supplemented by clinical validation partnerships with academic medical centers (Banner Alzheimer's Institute, Baycrest, UHN, Hamilton Health Sciences).
Revenue mechanics center on recurring licensing of the BrainSee diagnostic software to healthcare providers, supplemented by pharmaceutical partnerships for drug development support. The company is privately held, headquartered in Emeryville, CA with an additional Toronto office for Canadian business development, and operates with a small team (1–10 FTE). Strategic capital has come from Eisai (2020 Series Seed lead), SOMPO (2022), IT-Farm, and others, with total disclosed funding in the $10M+ range across multiple rounds.
Darmiyan firmographics
Firmographics- Name
- Darmiyan
- Legal name
- Darmiyan, Inc.
- Website
- https://darmiyan.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Darmiyan is a neuroscience-AI company whose FDA De Novo-approved BrainSee software (January 2024) provides the first AI-powered prognosis of Alzheimer's disease in patients with amnestic mild cognitive impairment, using its proprietary DarmiScope MRI analysis platform to serve healthcare providers, pharmaceutical companies, and senior-care networks.
- Ownership category
- akta.pro rank
Darmiyan industry classification
Industry- Product category
- AI Medical Diagnostics
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
- SIC
- Services-Prepackaged Software (7372), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where Darmiyan is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Darmiyan business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Revenue model
- BrainSee Diagnostic Software: Revenue generated from licensing BrainSee AI diagnostic software to healthcare providers for clinical evaluation of patients with mild cognitive impairment. The software helps physicians determine prognosis and likelihood of progression to Alzheimer's dementia.
- Pharmaceutical Partnerships: Using data to advance drug development for Alzheimer's disease. Partnerships with pharmaceutical companies for drug development support using the company's brain imaging and AI technology.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Darmiyan product offering
Product offeringCore offering
Darmiyan develops and licenses BrainSee, the first FDA-approved (De Novo, January 2024) AI-powered medical software that helps physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI). The software combines a patient's standard clinical brain MRI with cognitive test scores and generates a score between 0 and 100 indicating the likelihood of progression from MCI to Alzheimer's dementia. The technology is powered by DarmiScope, a patented Virtual Microscope that performs cellular-level quantification within every voxel of brain MRI scans with approximately 90% accuracy in predicting 5-year clinical prognosis.
Product overview
Darmiyan offers a unified platform focused on precision brain health screening and monitoring. The company's flagship product is BrainSee, an FDA-approved (De Novo, January 2024) AI-powered medical software that provides early detection and prognosis of Alzheimer's disease. BrainSee is powered by DarmiScope, the company's proprietary core technology that acts as a 'virtual microscope' analyzing brain MRI scans at the cellular level. BrainSee combines brain imaging with cognitive test scores to generate prognostic scores for patients with amnestic mild cognitive impairment. The company is developing additional brain tests as part of an 'a la carte menu of brain tests' starting with Alzheimer's testing, with technology applicable to other neurodegenerative disorders.
Differentiator
Problem solved
Functional benefit
Brands
- BrainSee: FDA-approved AI medical software designed to help physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI). BrainSee combines a patient's brain MRI with cognitive test scores to generate a score between 0 and 100 indicating likelihood of progression from MCI to Alzheimer's dementia.
Products and services
- BrainSee BrainSee is the first FDA-approved (De Novo, January 2024) AI-powered medical software designed to help physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI). It combines a patient's brain MRI with cognitive test scores and generates a score between 0 and 100 indicating the likelihood of progression from MCI to Alzheimer's dementia. It received FDA Breakthrough Device Designation in May 2021 and is designed for neurologists, radiologists, neuroradiologists, and primary care physicians evaluating patients with memory complaints.
- DarmiScope Virtual Microscope DarmiScope is the patented core Virtual Microscope technology that resolves tissue structure in every voxel of brain MRI, performing cellular-level quantification with approximately 90% accuracy to predict 5-year clinical prognosis of MCI. It is the foundational technology behind BrainSee and has applications across neurodegenerative disorders.
Quantifiable outcome
- ~90% accuracy in predicting 5-year clinical prognosis of MCI (blind testing of 411 cases with 5 years follow-up)
- +2 more outcomes
Companies that use Darmiyan
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Darmiyan technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Darmiyan partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered flagship, core and minor.
- California Association of Health Facilities (CAHF)flagshipCAHF designated Darmiyan as its preferred provider for cognitive health solutions, offering its members access to the FDA-approved AI tool BrainSee. This partnership aims to enhance early assessment and prevention of dementia among over 350,000 residents across California facilities.
- Center for Aging and Brain Health Innovation (CABHI)corePartnership with CABHI includes collaboration with partner sites Baycrest Institute, University Health Network (UHN) and Hamilton Health Sciences. Darmiyan won CABHI Innovation Award in 2019 and CABHI Industry Innovation (I2P2) award in 2018 for CAN $500K.
- Banner Alzheimer's InstitutecoreProof of concept study focused on early detection of Alzheimer's disease at preclinical (presymptomatic) stage. Partnership agreement signed in 2018 Q1.
- Boston UniversityminorPartnership agreement signed with Boston University in 2018 Q2 for collaboration in research and development.
- Mary Furlong & AssociatescoreStrategic partnership signed in 2019 Q3 with Mary Furlong & Associates for business development and marketing support in the longevity and brain health sector.
- MedscapecoreContent partnership launched in 2021 Q4 with Medscape, a leading medical information platform, to provide brain health educational content to physicians.
- GetSetupminorMounted brain health content series with GetSetup adult learning platform featuring Chief Medical and Technology Officer Dr. Kaveh Vejdani, yielding record registration levels.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Darmiyan competitors and assessment
Company assessmentDirect peers
- Altoida: Altoida develops a digital cognitive assessment platform using smartphone-based AR/AI tests to detect early signs of cognitive decline and predict conversion to AD. It targets the same early-MCI detection workflow as BrainSee but via cognitive testing rather than MRI.
- Cogstate: Cogstate provides computerized cognitive testing for clinical trials, healthcare providers, and research, including AD/MCI assessment. It is comparable to Darmiyan in supplying objective cognitive measurement to clinicians evaluating MCI patients and to pharma for trial endpoints.
- Quanterix: Quanterix's Simoa platform provides ultra-sensitive biomarker detection (including p-tau217, NfL) used for Alzheimer's disease diagnosis and monitoring. It competes with BrainSee in the objective early-detection-of-AD space, offering a complementary non-imaging modality.
- C2N Diagnostics: C2N Diagnostics commercializes PrecivityAD, a blood-based Alzheimer's diagnostic that, like BrainSee, addresses the early detection and prognosis of AD from a non-invasive specimen. Both companies are pursuing FDA-cleared prognostic tools for the MCI-to-AD conversion pathway.
- QMENTA: QMENTA operates an AI-powered neuroimaging platform for clinical trials and clinical practice, including brain MRI analysis for neurological disorders. It overlaps with Darmiyan in providing cloud-based brain imaging AI infrastructure to pharma and research institutions.
- icometrix: icometrix provides AI-based brain MRI analysis software (MSmetrix, icobrain) for quantification and monitoring of neurological conditions including MS, dementia, and TBI. It is a direct peer in AI-powered brain MRI SaaS sold to clinicians and pharma for neurodegenerative disease management.
- Cerveau Technologies: Cerveau develops and supplies tau PET imaging ligands used in Alzheimer's disease diagnosis and clinical trials. Like Darmiyan, Cerveau's tools are deployed to identify early/prodromal AD pathology and support pharmaceutical drug development programs.
- Cortechs.ai: Cortechs.ai markets NeuroQuant, an FDA-cleared MRI brain volumetric analysis tool used clinically to support neurological diagnosis and monitoring. Like Darmiyan, Cortechs applies AI/quantitative analysis to standard clinical brain MRI for neurodegenerative disease assessment.
- Linus Health: Linus Health offers a digital cognitive assessment platform (incorporating DCTclock and other AI-based pen-and-paper tests) for early detection of cognitive impairment. It addresses the same primary care / memory clinic workflow as BrainSee for MCI evaluation.
Broad incumbents
- Clario (formerly Bioclinica): Clario is a large clinical-trial technology and imaging CRO that provides MRI analysis and clinical-readout services to pharma sponsors, including for AD trials. It is comparable as an established pharma-services partner offering imaging-based AD endpoints, though broader in scope than Darmiyan's diagnostic focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Darmiyan social profiles
Digital presenceDarmiyan compliance and trust
Trust signalCompliance1 record
Darmiyan financial estimates
Financial estimateRevenue estimate
Valuation estimate
Darmiyan leadership team
Management profileNumber of profiles
Profiles8 records
Darmiyan funding detail
Funding detailFunding overview
Funding rounds6 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Darmiyan M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Darmiyan
What does Darmiyan do?
Darmiyan develops and licenses BrainSee, the first FDA-approved (De Novo, January 2024) AI-powered medical software that helps physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI). The software combines a patient's standard clinical brain MRI with cognitive test scores and generates a score between 0 and 100 indicating the likelihood of progression from MCI to Alzheimer's dementia. The technology is powered by DarmiScope, a patented Virtual Microscope that performs cellular-level quantification within every voxel of brain MRI scans with approximately 90% accuracy in predicting 5-year clinical prognosis.
Is Darmiyan a public or private company?
Darmiyan is a private company. It is classified as venture growth investor backed and is currently operating.
When was Darmiyan founded?
Darmiyan was founded in 2016. It employs 1 to 10 people.
Where is Darmiyan based?
Darmiyan is headquartered in San Francisco, United States, in the North America region.
How does Darmiyan make money?
Two revenue lines are on record. BrainSee Diagnostic Software is the primary driver. The others are pharmaceutical Partnerships.
Who are Darmiyan's main competitors?
Direct peers on record are Altoida, Cogstate, Quanterix, C2N Diagnostics, QMENTA, icometrix, Cerveau Technologies, Cortechs.ai and Linus Health. Clario (formerly Bioclinica) is listed as a broad incumbent.
Does Darmiyan have an API?
No public API is recorded for Darmiyan.
What industry is Darmiyan in?
Darmiyan's product category is AI Medical Diagnostics. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 621511 and its SIC code is 7372.